CGEM

8.8901.98%
DD

David D. Meek

Independent Director

Mr. David D. Meek, M.D., serves as an Independent Chairman of Swedish Orphan Biovitrum AB (publ) since December 11, 2024. He serves as Chief Executive Officer at Bluebird bio, Inc. Mr. Meek serves as Chairman of the Board and Chief Executive Officer of Stargazer Pharmaceuticals Inc. He serves as an Executive Chairman of Aminex Therapeutics Inc. He serves as Independent Director since May 2024 at Cullinan Therapeutics, Inc. He served as the Chief Executive Officer & Director at Mirati Therapeutics, Inc. since September 20, 2021 until 2023. He serves as Independent Director of Fusion Pharmaceuticals Inc. since October 16, 2023. He had been Independent Chairman of Entasis Therapeutics Holdings Inc. since June 24, 2019 and served as its Independent Director since 2019 until July 2022 (acquired by Innoviva, Inc.). He had been President & Chief Executive Officer of FerGene since January 2020 to March 2021. From July 2016 to December 2020, he was Chief Executive Officer and a Member of the Board of Ipsen Biopharmceuticals, Inc., a public biopharma company. He served as Industry Advisor at Agent Capital, LLC. He served as the Chief Executive Officer of Ipsen S.A. since July 18, 2016 until December 31, 2019. Prior to that, he served as an Executive Vice President and President of Oncology at Baxalta Incorporated from July 2014 to June 2016. He served as Baxter's Vice President, Global Head of Oncology since early 2014. He served as Chief Commercial Officer of Endocyte, Inc. from August 2012 to July 2014 and served as its Executive Officer from June 02, 2014 to August 29, 2014. He has been a Non-Executive Director of uniQure N.V. since June 13, 2018 and also serves as its Independent Non-Executive Chairman since June 16, 2021. He has pharmaceutical industry experience, including general management in North America and Europe and numerous successful launches for oncology and specialty products. He served at Novartis Pharma AG, where he served as the Head of northern and central Europe oncology and launched key new oncology products and indications for Novartis. Previously, he served as President and Chief Executive Officer of Novartis Pharmaceuticals Canada from 2007 to 2009, where he oversaw the launch of Lucentis and other specialty products and he also served as the global business franchise Head for Novartis' respiratory and dermatology franchise in Basel, Switzerland from 2005 to 2007. He was employed at Novartis from 2005 to 2012, where he served as President and Chief Executive Officer of the pharmaceutical division in Canada; and the region Head of Oncology for Northern, Central and Eastern Europe, based in Milan, Italy from 2010 to 2012. He started his career at Johnson & Johnson and Janssen Pharmaceuticals from 1989 to 2004 where he held a variety of U.S. senior sales and marketing positions across multiple therapeutic areas in primary care (gastroenterology, pain management, dermatology) and specialty care (oncology, neuroscience). Prior to joining Novartis, he was at Johnson & Johnson, where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology. He served as a Director of Ipsen S.A. since June 7, 2017 until December 31, 2019. He has industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology, including as CEO of Ipsen, a leading global biopharmaceutical company. Prior to that, he served in various executive leadership roles at Novartis Pharma and Novartis Oncology after beginning his career at Johnson & Johnson and Janssen from 1989 to 2004. He serves as a Director for Stargazer Pharmaceuticals. He has also served on the boards of Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA) and serves on the boards of uniQure N.V., Entasis Therapeutics Holdings Inc. and Stargazer Pharmaceuticals. He holds a B.A. in Management from the University of Cincinnati.

Positions